# CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

> **NCT05312398** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 219 (actual)

## Conditions studied

- Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** FOLFIRI
- **DRUG:** FOLFOX regimen
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05312398
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-15
- **Primary completion:** 2026-08-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312398, "CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05312398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*